Ikonisys Completes a Capital Increase and Debt Conversion of 2.72 Million Euros

On December 19, 2025, Ikonisys announced the completion of its capital increase and debt conversion, raising €2.72 million. The transaction included a €1.5 million capital injection through a private placement and the conversion of €1.22 million of debt. The participation of strategic investors, including Avantgarde Srl and Alberto Previtali, underscores confidence in Ikonisys' future. The new industrial strategy aims to strengthen its position in the oncology diagnostics market.

The funding obtained will be dedicated to business expansion and technological innovation, focusing on automation and artificial intelligence. Furthermore, Ikonisys is considering mergers and acquisitions to enrich its portfolio. The board of directors approved the transaction, eliminating shareholders' preferential subscription rights, with a 6% discount on the share price. The dilutive impact for a shareholder initially holding 1% of the capital is limited, decreasing to 0.89%.